We are thrilled to announce that MaaT Pharma, a trailblazer in the field of microbiome-driven immunomodulation, has successfully raised €13,000,000 in its latest funding round. Founded in 2014 and based in Lyon, France, MaaT Pharma has consistently positioned itself at the forefront of clinical innovation by developing pioneering therapies aimed at modulating the immune system to enhance the survival of cancer patients. As a leading late-stage clinical company, MaaT Pharma is driven by its commitment to harnessing the power of the gut microbiome to revolutionize oncology treatments. The recent capital infusion will further enable the company to accelerate its ambitious clinical programs as it brings the first microbiome-driven immunomodulator closer to market approval.
This significant funding milestone not only reinforces investor confidence in MaaT Pharma’s novel therapeutic approach and proprietary pooling and co-cultivation technologies but also underscores the potential of harnessing high diversity, standardized drug candidates to extend the life of cancer patients. Since its listing on Euronext Paris under the ticker MAAT in 2021, the company has built a strong reputation for scientific excellence and transformative innovation. The newly raised funds will be dedicated to advancing key clinical studies, driving further research and development initiatives, and expanding commercial capabilities to reach a broader patient population globally. With a talented team of experts committed to making a tangible difference in patients’ lives, MaaT Pharma is poised to lead the next wave of groundbreaking treatments in oncology, offering renewed hope and improved outcomes for cancer patients worldwide.
